Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy

BMC Cancer

Nan Bi¹  Jima Lv¹  Jianyang Wang¹  Zefen Xiao¹  Yu Men¹  Qinfu Feng¹  Jun Liang¹  Luhua Wang¹  Zongmei Zhou¹  Dongfu Chen¹  Zhouguang Hui²  Wenhui Wang³  Shu Geng Gao⁴ 

[1] 0000 0001 0662 3178, grid.12527.33, Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academic of Medical Sciences and Peking Union Medical College, 100021, Beijing, China;0000 0001 0662 3178, grid.12527.33, Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academic of Medical Sciences and Peking Union Medical College, 100021, Beijing, China;0000 0001 0662 3178, grid.12527.33, Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academic of Medical Sciences and Peking Union Medical College, Panjiayuan Nanli #17, Chaoyang District, 100021, Beijing, China;0000 0001 0662 3178, grid.12527.33, Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academic of Medical Sciences and Peking Union Medical College, 100730, Beijing, China;0000 0001 0662 3178, grid.12527.33, Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academic of Medical Sciences and Peking Union Medical College, 100021, Beijing, China;

关键词: Non-small-cell lung cancer;    Stage pIII-N2;    Pneumonectomy;    Postoperative radiotherapy;   

DOI  :  10.1186/s12885-019-5692-3

来源: publisher

【 摘 要 】

BackgroundThere were few reports of postoperative radiotherapy (PORT) in stage pIII-N2 Non-small-cell Lung Cancer (NSCLC) patients receiving pneumonectomy followed by adjuvant chemotherapy. This study aims to evaluate safety and efficacy of PORT among these patients.MethodsBetween Jan. 2004 and Dec. 2015, stage pIII-N2 NSCLC patients receiving pneumonectomy and adjuvant chemotherapy with or without PORT in our institution were retrospectively reviewed.ResultsTotally 119 patients were included, 32 patients receiving adjuvant chemotherapy and PORT (PORT group) and 87 receiving adjuvant chemotherapy alone (Control group). There were more patients with non-R0 resection in PORT group than Control group (25% vs. 8%, p = 0.031). In PORT group, ≥Grade 2 radiation-induced pneumonitis was 2/32. No severe radiation-related heart injury was observed. There was no PORT-related death. Of all patients, median follow-up time was 25 months. Median overall survival time (mOS) and median disease-free survival time (mDFS) were 46 months and 15 months, respectively. The PORT group had significantly better OS (not reached vs. 34 months, p = 0.003), DFS (19 months vs. 13 months, p = 0.024), local recurrence free survival (LRFS, p = 0.012), and distant metastasis free survival (DMFS, p = 0.047) than the Control group. As for failure pattern, PORT significantly reduced local regional failure rate (39.1% vs. 15.6%, p = 0.016). In subgroup analysis, patients with R0 resection (n = 104), OS and LRFS in PORT group were significantly longer, and PORT tended to increase DFS and DMFS.ConclusionFor patients with stage pIII-N2 NSCLC after pneumonectomy and adjuvant chemotherapy, PORT can improve OS, DFS, LRFS and DMFS with tolerable toxicity.

【 授权许可】

CC BY